Table 1

Summary of trials

Disease stageEarly systemicMild–moderate renalSevere renalMild–moderate renal
Remission inductionMTX+OCS/poCYC+OCSpoCYC+OCSivMP+poCYC+OCS vs PE+poCYC+OCSivCYC+OCS vs poCYC+OCS
Remission maintenanceMTX+OCS or poCYC+OCSpoCYC+OCS vs AZA+OCSAZA+OCSAZA+OCS
  • CYCAZAREM, randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis; CYCLOPS, randomised trial of daily oral versus pulsed cyclophosphamide for the treatment of ANCA-associated vasculitis; MEPEX, randomised trial of adjunctive treatment for severe glomerulonephritis in ANCA-associated systemic vasculitis, plasma-exchange versus intravenous methylprednisolone; NORAM, efficacy of methotrexate versus cyclophosphamide in the treatment of ‘non-renal’ Wegener's granulomatosis.

  • AZA, azathioprine; ivCYC, intravenous cyclophosphamide; poCYC, oral cyclophosphamide; ivMP, intravenous methylprednisolone; MTX, methotrexate; OCS, oral corticosteroids; PE, plasma exchange.